Enliven Therapeutics Reports Q2 2026 Financial Results

What Happened

• Enliven Therapeutics, Inc. (ELVN) filed a Form 8‑K on August 5, 2026 (Item 2.02) to announce its financial results for the quarter ended June 30, 2026. The company issued a press release on that date announcing the quarterly results; the full text of the release is attached to the 8‑K as Exhibit 99.1 and incorporated by reference.

Key Details

• Filing date: August 5, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Disclosure format: The company furnished a press release (Exhibit 99.1) with the results; the exhibit is stated as “furnished” and therefore is not deemed “filed” for purposes of Section 18 of the Exchange Act (Item 9.01 note).
• The 8‑K points investors to the attached press release for the detailed financial figures and commentary.

Why It Matters

• This filing signals that Enliven has publicly released its quarterly earnings information; investors should review the attached press release (Exhibit 99.1) for revenue, earnings/loss, cash position, and any guidance or operational updates.
• The “furnished, not filed” status limits certain legal liabilities for the attachment, so investors should rely on the press release content for timely financial data but also watch for subsequent filings (e.g., 10‑Q) for the formal, filed financial statements and detailed disclosures.